Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evercore (EVR) Notes Payables (2016 - 2025)

Evercore has reported Notes Payables over the past 16 years, most recently at $48.0 million for Q4 2025.

  • Quarterly results put Notes Payables at $48.0 million for Q4 2025, up 26.43% from a year ago — trailing twelve months through Dec 2025 was $48.0 million (up 26.43% YoY), and the annual figure for FY2025 was $48.0 million, up 26.43%.
  • Notes Payables for Q4 2025 was $48.0 million at Evercore, roughly flat from $48.0 million in the prior quarter.
  • Over the last five years, Notes Payables for EVR hit a ceiling of $376.2 million in Q4 2021 and a floor of $37.9 million in Q3 2024.
  • Median Notes Payables over the past 5 years was $370.5 million (2022), compared with a mean of $235.4 million.
  • Biggest five-year swings in Notes Payables: soared 890.79% in 2021 and later plummeted 89.82% in 2024.
  • Evercore's Notes Payables stood at $376.2 million in 2021, then dropped by 1.19% to $371.8 million in 2022, then grew by 0.17% to $372.4 million in 2023, then tumbled by 89.81% to $38.0 million in 2024, then increased by 26.43% to $48.0 million in 2025.
  • The last three reported values for Notes Payables were $48.0 million (Q4 2025), $48.0 million (Q3 2025), and $85.9 million (Q2 2025) per Business Quant data.